Solara Active Pharma Sciences Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.4K Cr
The company is focusing on the growth API business, which is showing healthy expansion and good margin profiles. The company is focusing on building its growth API business, which is delivering healthy gross margins (~56%) and EBITDA (~25%), higher than the industry average.
From Solara Active Pharma Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹617
Market Cap
₹2.4K Cr
P/E Ratio
573.4
How does Solara Active Pharma Sciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Solara Active Pharma Sciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹387 Cr, net profit ₹10 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company is focusing on the growth API business, which is showing healthy expansion and good margin profiles.
- →Current capacity utilization in the growth API segment is about 70%.
- →The Vizag facility is being revamped into a multipurpose and high-potent API plant to support future growth.
- →Launch of new APIs, including one associated with OneSource, is expected by FY '27, indicating upcoming revenue opportunities.
- →The company is cautious about giving specific guidance for API growth until resolution and strategic decisions regarding the ibuprofen business are finalized.
- →Overall revenue growth is expected to be driven primarily by the non-ibuprofen, high-margin API portfolio.
- →Operational efficiencies are being improved to enhance EBITDA flow-through and margin expansion.
- →Corporate actions and investment focus will continue around the profitable growth API segment, with ibuprofen business undergoing strategic review.
📈 Profitability & Margins
- →The company is focusing on building its growth API business, which is delivering healthy gross margins (~56%) and EBITDA (~25%), higher than the industry average.
- →Operational efficiencies are a key focus to improve EBITDA flow-through in the API business, currently with gross margins around 55%.
- →The ibuprofen base business is facing significant challenges due to pricing pressure and excess capacity, impacting consolidated margins.
- →Strategic options for the ibuprofen business are under review, with clarity expected by Q4 FY '26 results.
- →No specific growth guidance or EPS forecast has been provided yet, as the company awaits decisions on ibuprofen and business restructuring.
- →Vizag facility is being converted into a multipurpose, high potent API plant to support future growth.
- →Continuous R&D investments aim to feed the growth API business and launch new products (e.g., with OneSource in FY '27).
- →Management emphasizes patience and trust as they work towards profitable and scalable growth across portfolios.
🏗️ Capital Expenditure Plans
- →Significant investments are underway to convert the Vizag facility from a single-product ibuprofen plant to a multipurpose plant and a high-potent API plant.
- →Investments include converting one of the blocks at Vizag for multipurpose use and another for high-potent API production.
- →R&D capabilities are being revived and enhanced to support the new operational focus at Vizag, with new talent onboarded.
- →Planned capital infusion will focus on building the growth API business, with a clear intent to ramp up Vizag back into commercial production within the next 5 to 6 months.
- →No specific monetary guidance given yet on capex or strategic investment figures; further clarity expected by Q4 FY '26 results.
- →Current focus on operational efficiency and cost structure optimization to improve EBITDA flow-through.
💰 Fundraising & Capital Structure
- →No explicit mention of new fundraising through debt or equity in the transcript.
- →The company has focused on reducing debt by INR146 crores via operational cash flow and rights issue proceeds, aiming to reduce debt to below INR500 crores by May 2026.
- →Current strategy emphasizes improving operational efficiency and focusing on profitable growth businesses rather than raising new funds.
- →Corporate actions, including potential restructuring or asset sales related to the ibuprofen business, are delayed until further clarity after Q4 results.
- →The company is investing in R&D and facility upgrades (e.g., converting Vizag to multipurpose/high potent API plant) using internal resources.
- →No specific guidance or announcement on future debt or equity fundraising was provided during the call.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Solara Active Pharma Sciences Ltd Q3 FY26 results?
The company is focusing on the growth API business, which is showing healthy expansion and good margin profiles. The company is focusing on building its growth API business, which is delivering healthy gross margins (~56%) and EBITDA (~25%), higher than the industry average.
What is Solara Active Pharma Sciences Ltd share price analysis?
Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 573.4 with a market cap of ₹2,448 Cr. Investors should review the full earnings analysis for detailed insights.
Is Solara Active Pharma Sciences Ltd planning capital expenditure?
Significant investments are underway to convert the Vizag facility from a single-product ibuprofen plant to a multipurpose plant and a high-potent API plant.
Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.